ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluate the Incidence of HFSR or PPE Syndrome in Patients With GI Cancers Treated With Fruquintinib | VuMedi

Find latest Colon Cancer videos · 400+ videos

This video is featured in the Insights from 2025 ASCO® GI Annual Meeting

Insights from 2025 ASCO® GI Annual Meeting

ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluate the Incidence of HFSR or PPE Syndrome in Patients With GI Cancers Treated With Fruquintinib

By Insights from 2025 ASCO® GI Annual Meeting FEATURING Kyaw Thein

By Insights from 2025 ASCO® GI Annual Meeting FEATURING Kyaw Thein

199 views

February 10, 2025

Comments 0

Login to view comments. Click here to Login